Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2008

View Archived Issues

Mechanistic and phase II data on HIV vaccine (PE)HRG214 presented

HIV-1-specific responses seen with vaccine candidate MVA-B in phase I study

DNGR-1 receptor allows antigen targeting to dendritic cell subsets and tumor therapy

Recent patents describe new antiglaucoma agents

Novel oncolytic agents disclosed in recent patent literature

Morphotek signs license agreement with NCI for monoclonal antibody for prostate cancer

Threshold initiates phase I/II clinical trial of TH-302 in solid tumors

Tekmira and Bristol-Myers enter RNAi research collaboration

Karo Bio and Wyeth extend atherosclerosis collaboration until August 2009

Dendreon initiates phase II ProACT trial of Provenge in prostate cancer

Moberg Derma reports promising results from phase III study of K-301 in seborrheic dermatitis

Palatin reports results from phase IIa clinical trial of PL-3994 in heart failure

Pharmaxis completes enrollment in phase III clinical trial of Bronchitol in cystic fibrosis

A novel FAAH inhibitor effective in inflammatory and neuropathic pain models

nNOS inhibitors active in neuropathic pain model

Cytos and Pfizer sign research and license agreement for certain novel vaccines

DSMB recommends continuation of phase III clinical trial of Bioniche's Urocidin

Yakult to initiate Japanese preclinical and clinical studies of ThermoDox in liver cancer

EMEA accepts for review Introgen's MAA for Advexin

Dyax reports topline results from EDEMA4 phase III clinical trial of DX-88 in HAE

Access and Milestone signed definitive license agreement for MuGard in North America

PregLem initiates phase III clinical trial program for PGL-4001 in uterine myoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...